We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novavax, Inc. (NVAX - Free Report) was a big mover last session, as the company saw its shares rise nearly 8% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up 43.2% in the past one-month time frame.
The move came after the company reported the initiation of phase 2 clinical trial of NanoFlu in older adults.
The company has seen one positive estimate revision in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved higher over the past few weeks, suggesting that more solid trading could be ahead for Novavax. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.
Novavax currently has a Zacks Rank #3 (Hold) while its Earnings ESP is positive.
Is NVAX going up? Or down? Predict to see what others think: Up or Down
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
Image: Bigstock
Novavax (NVAX) Catches Eye: Stock Jumps 7.6%
Novavax, Inc. (NVAX - Free Report) was a big mover last session, as the company saw its shares rise nearly 8% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up 43.2% in the past one-month time frame.
The move came after the company reported the initiation of phase 2 clinical trial of NanoFlu in older adults.
The company has seen one positive estimate revision in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved higher over the past few weeks, suggesting that more solid trading could be ahead for Novavax. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.
Novavax currently has a Zacks Rank #3 (Hold) while its Earnings ESP is positive.
Novavax, Inc. Price
Novavax, Inc. Price | Novavax, Inc. Quote
A better-ranked stock in the Medical - Biomedical and Genetics industry is Anika Therapeutics Inc. (ANIK - Free Report) , which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is NVAX going up? Or down? Predict to see what others think: Up or Down
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>